Christine Fritsch

Basel, BS, Switzerland

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 13 publications

N-acetylcysteine overcomes NF1 loss-driven resistance to PI3Kα inhibition in breast cancer.

N-acetylcysteine overcomes NF1 loss-driven resistance to PI3Kα inhibition in breast cancer.

Journal: Cell reports. Medicine

Published: August 08, 2022

Increasing metabolic stability via the deuterium kinetic isotope effect: An example from a proline-amide-urea aminothiazole series of phosphatidylinositol-3 kinase alpha inhibitors.

Increasing metabolic stability via the deuterium kinetic isotope effect: An example from a proline-amide-urea aminothiazole series of phosphatidylinositol-3 kinase alpha inhibitors.

Journal: Bioorganic & medicinal chemistry letters

Published: June 17, 2016

Identification of N-(4-((1R,3S,5S)-3-Amino-5-methylcyclohexyl)pyridin-3-yl)-6-(2,6-difluorophenyl)-5-fluoropicolinamide (PIM447), a Potent and Selective Proviral Insertion Site of Moloney Murine Leukemia (PIM) 1, 2, and 3 Kinase Inhibitor in Clinical Trials for Hematological Malignancies.

Identification of N-(4-((1R,3S,5S)-3-Amino-5-methylcyclohexyl)pyridin-3-yl)-6-(2,6-difluorophenyl)-5-fluoropicolinamide (PIM447), a Potent and Selective Proviral Insertion Site of Moloney Murine Leukemia (PIM) 1, 2, and 3 Kinase Inhibitor in Clinical Trials for Hematological Malignancies.

Journal: Journal of medicinal chemistry

Published: October 28, 2015

Activation of IGF1R/p110β/AKT/mTOR confers resistance to α-specific PI3K inhibition.

Activation of IGF1R/p110β/AKT/mTOR confers resistance to α-specific PI3K inhibition.

Journal: Breast cancer research : BCR

Published: September 10, 2015

Identification and optimisation of 4,5-dihydrobenzo[1,2-d:3,4-d]bisthiazole and 4,5-dihydrothiazolo[4,5-h]quinazoline series of selective phosphatidylinositol-3 kinase alpha inhibitors.

Identification and optimisation of 4,5-dihydrobenzo[1,2-d:3,4-d]bisthiazole and 4,5-dihydrothiazolo[4,5-h]quinazoline series of selective phosphatidylinositol-3 kinase alpha inhibitors.

Journal: Bioorganic & medicinal chemistry letters

Published: May 28, 2015

Identification and optimisation of a 4',5-bisthiazole series of selective phosphatidylinositol-3 kinase alpha inhibitors.

Identification and optimisation of a 4',5-bisthiazole series of selective phosphatidylinositol-3 kinase alpha inhibitors.

Journal: Bioorganic & medicinal chemistry letters

Published: May 13, 2015

Discovery of a novel tricyclic 4H-thiazolo[5',4':4,5]pyrano[2,3-c]pyridine-2-amino scaffold and its application in a PI3Kα inhibitor with high PI3K isoform selectivity and potent cellular activity.

Discovery of a novel tricyclic 4H-thiazolo[5',4':4,5]pyrano[2,3-c]pyridine-2-amino scaffold and its application in a PI3Kα inhibitor with high PI3K isoform selectivity and potent cellular activity.

Journal: Bioorganic & medicinal chemistry letters

Published: May 12, 2015

Characterization of the novel and specific PI3Kα inhibitor NVP-BYL719 and development of the patient stratification strategy for clinical trials.

Characterization of the novel and specific PI3Kα inhibitor NVP-BYL719 and development of the patient stratification strategy for clinical trials.

Journal: Molecular cancer therapeutics

Published: March 11, 2014

Pan-PIM kinase inhibition provides a novel therapy for treating hematologic cancers.

Pan-PIM kinase inhibition provides a novel therapy for treating hematologic cancers.

Journal: Clinical cancer research : an official journal of the American Association for Cancer Research

Published: January 30, 2014

Discovery of NVP-BYL719 a potent and selective phosphatidylinositol-3 kinase alpha inhibitor selected for clinical evaluation.

Discovery of NVP-BYL719 a potent and selective phosphatidylinositol-3 kinase alpha inhibitor selected for clinical evaluation.

Journal: Bioorganic & medicinal chemistry letters

Published: March 25, 2013

Hematopoiesis and RAS-driven myeloid leukemia differentially require PI3K isoform p110α.

Hematopoiesis and RAS-driven myeloid leukemia differentially require PI3K isoform p110α.

Journal: The Journal of clinical investigation

Published: March 15, 2013

Characterization of the mechanism of action of the pan class I PI3K inhibitor NVP-BKM120 across a broad range of concentrations.

Characterization of the mechanism of action of the pan class I PI3K inhibitor NVP-BKM120 across a broad range of concentrations.

Journal: Molecular cancer therapeutics

Published: June 02, 2012

Showing 1-12 of 13

Last Updated: 09/26/2026